(IN BRIEF) The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, marking a significant step in managing this condition in a critical developmental phase. The approval is … Read the full press release →
Posted in Business, Education, European Union, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Dr. George Yancopoulos, Dr. Houman Ashrafian, Dupixent, eosinophilic esophagitis, EU, European Medicines Agency (EMA), Healthcare, Regeneron, safety, Sanofi, treatment, wellness, Young Children